secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edgewise Therapeutics, Inc. (EWTX)
CIK:        0001710072
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001104659-24-057783
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edgewise Therapeutics appoints Arlene Morris to Board of Directors, effective May 6, 2024
--------------------------------------------------------------------------------

- Morris replaces Peter Thompson on the Audit and Compensation Committees.
- She brings 30+ years of biotech leadership, including CEO roles at Syndax and Affymax.
- Annual cash retainer of $40,000 plus $7,500 for Audit and $5,000 for Compensation Committee service.
- New director stock option grant with ~$500,000 fair value, vesting monthly over 3 years.
- Appointment fills vacancy left by Kenneth Harrison's resignation in June 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710072/000110465924057783/0001104659-24-057783-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710072/000110465924057783/tm2413446d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-057783

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer